Orlando – AACR23 is in full swing and one of the areas gaining a lot of attention at the meeting is a surfeit of new data on targeting KRAS.

In this post we review some of the key data presented so far, along with commentary from some of the education sessions we’ve covered, which not everyone may have attended.

Can we beat KRAS and, if not, what are the challenges to be overcome? How should we go about this endeavour?  Is it all sun and palm trees in Florida?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by